Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Bristol-Myers Squibb (NYSE:BMY) and maintained a $50 price target.
October 18, 2024 | 11:56 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating for Bristol-Myers Squibb, maintaining a $50 price target, indicating no expected short-term price movement.
The reiteration of a Neutral rating and maintenance of the $50 price target by Cantor Fitzgerald suggests that the analyst does not foresee significant short-term changes in the stock's price. This indicates stability in the current valuation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100